tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

EFTR Stock Latest News

eFFECTOR Therapeutics Initiates Wind-Down and Leadership Change
Company AnnouncementseFFECTOR Therapeutics Initiates Wind-Down and Leadership Change
3M ago
8K
EFTR
Twelve option delistings on June 24th
PremiumThe Fly
Twelve option delistings on June 24th
3M ago
ENG
RGS
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
PremiumPress Releases
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
3M ago
EFTR
eFFECTOR to wind down operations, expects to be delisted from Nasdaq
PremiumThe Fly
eFFECTOR to wind down operations, expects to be delisted from Nasdaq
3M ago
EFTR
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
PremiumPress Releases
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
4M ago
EFTR
eFfector Therapeutics to collaborate with Dana-Farber Cancer Institute
PremiumThe FlyeFfector Therapeutics to collaborate with Dana-Farber Cancer Institute
4M ago
EFTR
eFfector Therapeutics reports Q1 EPS ($2.16), consensus ($2.16)
Premium
The Fly
eFfector Therapeutics reports Q1 EPS ($2.16), consensus ($2.16)
4M ago
EFTR
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Premium
Press Releases
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4M ago
EFTR
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
PremiumPress Releases
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
5M ago
EFTR
eFFECTOR Therapeutics trading resumes
PremiumThe Fly
eFFECTOR Therapeutics trading resumes
6M ago
EFTR
eFfector sees no ‘obvious’ path forward for tomivosertib development in NSCLC
PremiumThe Fly
eFfector sees no ‘obvious’ path forward for tomivosertib development in NSCLC
6M ago
EFTR
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
PremiumPress Releases
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
6M ago
EFTR
eFFECTOR Therapeutics trading halted, news pending
PremiumThe FlyeFFECTOR Therapeutics trading halted, news pending
6M ago
EFTR
Effector Therapeutics’ Stock Issuance Capped: Navigating the Lincoln Park Agreement’s Exchange Limit
Premium
Company Announcements
Effector Therapeutics’ Stock Issuance Capped: Navigating the Lincoln Park Agreement’s Exchange Limit
6M ago
EFTR
eFfector Therapeutics reports Q4 EPS ($3.42), consensus ($1.65)
Premium
The Fly
eFfector Therapeutics reports Q4 EPS ($3.42), consensus ($1.65)
6M ago
EFTR
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
6M ago
EFTR
EFTR Earnings this Week: How Will it Perform?
PremiumPre-Earnings
EFTR Earnings this Week: How Will it Perform?
6M ago
EFTR
eFfector Therapeutics target adjusted to $24 at H.C. Wainwright
PremiumThe Fly
eFfector Therapeutics target adjusted to $24 at H.C. Wainwright
8M ago
EFTR
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
PremiumPress Releases
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
8M ago
EFTR
eFFECTOR Therapeutics Regains Nasdaq Compliance Status
PremiumCompany AnnouncementseFFECTOR Therapeutics Regains Nasdaq Compliance Status
8M ago
8K
EFTR
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Premium
Press Releases
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
8M ago
EFTR
eFFECTOR Therapeutics Secures $15M in Direct Offering
Premium
Market News
eFFECTOR Therapeutics Secures $15M in Direct Offering
8M ago
8K
EFTR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >